Integration of patient-reported outcomes in multiregional confirmatory clinical trials

Contemporary Clinical Trials

Volumn 35, Issue 1, 2013, Pages 62-69

  Gnanasakthy, Ari ^a   DeMuro, Carla ^b   Boulton, Caroline ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b RTI HEALTH SOLUTIONS   (United States)

Author keywords

Culture and literacy; Multiregional clinical trials; Regulatory challenges

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG INDUSTRY; DRUG MANUFACTURE; EMOTION; HUMAN; PATIENT REPORTED OUTCOME; PRACTICE GUIDELINE; PUBLIC HEALTH; REVIEW; SELF REPORT; TREATMENT OUTCOME;

BIAS (EPIDEMIOLOGY); DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; HUMANS; MULTICENTER STUDIES AS TOPIC; PATIENTS; TREATMENT OUTCOME;

EID: 84875242969     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2013.02.006     Document Type: Review

References (45)

1. Doward L.C., Gnanasakthy A., Baker M.G. Patient reported outcomes: looking beyond the label claim. Health Qual Life Outcomes 2010, 8.
2. Getz K.A., Wenger J., Campo R.A., Seguine E.S., Kaitin K.I. Assessing the impact of protocol design changes on clinical trial performance. Am J Ther Sep-Oct 2008, 15(5):450-457.
3. Gnanasakthy A., Mordin M., Clark M., DeMuro C., Fehnel S., Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value in health 2012, [Available at: http://www.sciencedirect.com/science/article/pii/S1098301511036011. Accessed February 2, 2012].
4. US Department of Health Human Services, Food and Drug Administration Guidance for industry: systemic lupus erythematosus-developing medical products for treatment 2010, [Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072063.pdf. Accessed January 21, 2012].
5. European Medicines Association (EMA), Committee for Medicinal Products for Human Use (CHMP) Reflection paper on the regulatory guidance for the use of Health Related Quality of Life (HRQL) measures in the evaluation of medicinal products July 27, 2005, EMA, London, [Ref No.: EMA/CHMP/EWP/139391/2004].
6. US Department of Health and Human Services, Food and Drug Administration Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims December 2009, [Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed January 20, 2012].
7. Gliklich R., Leavy M. Patient registries and rare diseases. Applied Clinical Trials 2011, 20(3).
8. European Medicines Association (EMA) Biomarkers Qualification program reference 2008.
9. US Department of Health and Human Services, Food and Drug Administration Guidance for industry. Qualification process for drug development tools. Center for Drug Evaluation and Research (CDER). Draft guidance October 2010, [Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf. Accessed January 20, 2012].
10. US Food and Drug Administration Critical path initiative Available at, [Accessed March 15, 2012]. http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm.
11. Coons S.J., Kothari S., Monz B.U., Burke L.B. The patient-reported outcome (PRO) consortium: filling measurement gaps for pro end points to support labeling claims. Clin Pharmacol Ther 2011 Nov, 90(5):743-748.
12. Innovative Medicine Initiative (IMI) IMI improves funding and simplifies rules for project participants. IMI fact sheet 2011, [Available at http://www.euresearch.ch/fileadmin/documents/PdfDocuments/FactSheetIMINewFundingRulesFinal_1_.pdf. Accessed January 16, 2012].
13. Kamel N., Compton C., Middelveld R., Higenbottam T., Dahlén S.E. The Innovative Medicines Initiative (IMI): a new opportunity for scientific collaboration between academia and industry at the European level. Eur Respir J May 2008, 31(5):924-926.
14. Wagner J.A., Prince M., Wright E.C., Ennis M.M., Kochan J., Nunez D.J., et al. The biomarkers consortium: practice and pitfalls of open-source precompetitive collaboration. Clin Pharmacol Ther May 2010, 87(5):539-542.
15. McKanzie J.A. Responding to emerging diseases: reducing the risks through understanding the mechanisms of emergence. J WPSAR 2011, 2(1).
16. Thiers F.A., Sinskey A.J., Berndt E.R. Trends in the globalization of clinical trials. Nat Rev Drug Discov 2008, 7(1):13-14.
17. McKenna S.P., Doward L.C. Integrating patient-reported outcomes. Value Health 2004, 7:9-12.
18. Records K., Keller C., Ainsworth B., Permana P. Instrument selection for randomized controlled trials: why this and not that?. Contemp Clin Trials Jan 2012, 33(1):143-150.
19. Patrick D.L., Burke L.B., Powers J.H., Scott J.A., Rock E.P., Dawisha S., et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007, 10:S125-S137.
20. Swaine-Verdier A., Doward L., Hagell P., Thorsen H., McKenna S. Adapting quality of life instruments. Value Health 2004, 7(1):S27-S30.
21. Wild D., Eremenco S., Mear I., Martin M., Houchin C., Gawlicki M., et al. Multinational trials-recommendations on the translations required, approaches to using the same language in different countries, and the approaches to support pooling the data: the ISPOR patient-reported outcomes translation and linguistic validation good research practices task force report. Value Health 2009, 12(4):430-440.
22. Conway K., Patrick D., Gauchon T., Acquadro C. Enhancing cross-cultural appropriateness for newly developed patient-reported outcome (pro) instruments: the use of translatability assessment. PRO Newsletter 2010, 44:9-12. [Fall Issue, Available from: http://www.pro-newsletter.com/images/PDF/final_pronl_44b%28all%E9g%E9%29.pdf. Accessed March 15, 2012].
23. Faresjö A., Anastasiou F., Lionis C., Johansson S., Wallander M.A., Faresjö T. Health-related quality of life of irritable bowel syndrome patients in different cultural settings. Health Qual Life Outcomes 2006, 4:21.
24. Melby M.K., Lock M., Kaufert P. Culture and symptom reporting at menopause. Hum Reprod Update 2005, 11(5):495-512.
25. Waza K., Graham A.V., Zyzanski S.J., Inoue K. Comparison of symptoms in Japanese and American depressed primary care patients. Fam Pract 1999, 16:528-533.
26. Komesaroff P.A., Thomas S. Combating the obesity epidemic: cultural problems demand cultural solutions. Intern Med J May 2007, 37(5):287-289.
27. Rahangdale L., Banandur P., Sreenivas A., Turan J.M., Washington R., Cohen C.R. Stigma as experienced by women accessing prevention of parent-to-child transmission of HIV services in Karnataka, India. AIDS Care Jul 2010, 22(7):836-842.
28. Census India India at a glance. Number of literates & literacy rate [Accessed Feb 9, 2012]. http://www.censusindia.gov.in/Census_Data_2001/India_at_glance/literates1.aspx.
29. World Health Organization (WHO) The health of the people: the African Regional Health Report 2006, WHO, Geneva.
30. Reinier K., Stecker E.C., Vickers C. Incidence of sudden cardiac arrest is higher in areas of low socioeconomic status: a prospective two year study in a large United States community. Resuscitation 2006, 70:186-192.
31. Page J.B. The concept in culture: a core issue in health disparities. J Urban Health 2005, 82:11135-11142.
32. Dilworth-Anderson P., Pierre G., Hillard T.S. Social justice, health disparities and culture and care in the elderly. J Law Med Ethics 2006, 40(1):26-32.
33. Hyder A.A., Wali S.A. Informed consent and collaborative research: perspectives from the developing world. Dev World Bioeth 2006, 6(1):33-40.
34. Diallo D., Doumbo O., Plowe C., Wellems T.E., Emanuel E.J., Hurst S.A. Community permission for medical research in developing countries. Clin Infect Dis Jul 15 2005, 41(2):255-259.
35. Anfray C., Emery M.P., Conway K., Acquadro C. Questions of copyright. Health Qual Life Outcomes Jan 31 2012, 10:16.
36. DeMuro C., Mordin M., Clark M., Evans E., Copley-Merriman K., Fehnel S., et al. Reasons for rejection of PRO label claims: an analysis based on a review of PROs among new molecular entities and biologic license applications 2006-2010. Poster presented at: International Society for Pharmacoeconomics and Outcomes Research 16th Annual International Meeting; May 2011; Baltimore, MD 2011.
37. Nijsten T., Meads D., deKorte J., Sampagna F., Gelfand J., Ongenae K., et al. Cross-cultural inequivalence of dermatology-specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol 2007, 127:2315-2322.
38. Tebbey P.W., Rink C. Target product profile: a renaissance for its definition and use. J Med Mark 2009, 9(4):301-307.
39. Marquis P., Caron M., Emery M.P., Scott J.A., Arnould B., Acquadro C. The role of Health Related Quality of Life data in drug approval process. Pharm Med 2011, 25(3):147-160.
40. Mordin M., Lewis S., Gnanasakthy A., Demuro-Mercon C., Copley-Merriman K., Fehnel S. Patient-reported outcomes as mentioned in product development guidance. Value Health 2010, 13(3):A17-A18.
41. European Medicines Agency Points to consider on clinical investigation of medicinal products other than NSAIDs for the treatment of rheumatoid arthritis Available at.
42. Girman C., Ibia E., Menjoge S., Mak C., Chen J., Agarwal A., et al. Regulatory Requirements for Trial Endpoints in multiregional clinical trials. Drug Inf J 2011, 45:587-594.
43. Baldwin M., Spong A., Doward L., Gnanasakthy A. Patient-reported outcomes, patient-reported information from randomized controlled trials to the social web and beyond. Patient 2011, 4(1):11-17.
44. Mbonu Ngozi C., Van Den Borne Bart, De Vries Nanne K. Stigma of people with HIV/AIDS in Sub-Saharan Africa: a literature review. J Trop Med 2009, [vol. 2009, Article ID 145891, 14 pages]. 10.1155/2009/145891.
45. Clyne Michael G. Pluricentric languages: differing norms in different nations 1992, Mouton De Gruyter, Berlin, [Print].